BRAF and melanoma: The V600E mutation of BRAF occurs in approximately 50% of melanoma tumors, and in these the selective BRAFV600E inhibitor, vemurafenib, provides on average >7 months of progression-free survival, although as many as 50% of these patients do not respond in spite of having the mutation in their tumors [26].